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COMPARATIVE FITNESS ANALYSIS OF PROTEOLYTIC CLEAVAGE SITE 
VACCINE VARIANTS IN SIMIAN IMMUNODEFICIENCY VIRUS 
FRANCES Y CHIANG 
ABSTRACT 
 Over the past few decades, the human immunodeficiency virus and its progression 
to acquired immunodeficiency syndrome has become one of the most prominent global 
health issues. As the number of infected persons continues to grow, it is increasingly 
important to develop a protective vaccine to stop HIV transmission, and a cure for those 
already infected. Although current combination antiretroviral therapy can help patients 
maintain undetectable levels of the virus throughout their bodies, once the treatment is 
stopped, the virus will rebound. In this project, the effects of a vaccine therapy that 
targets the protease cleavage sites (PCS) of the HIV protease were evaluated in 16 
Cynomolgus macaques. Preliminary results of the study show that in the vaccine group 
(n=11), a disruption to one or more of the HIV protease cleavage sites leads to a better 
maintenance of CD4+ T cells versus that in the control group (n=5). Furthermore, a 
correlation between the percentage of PCS mutations and viral load was also observed. 
Upon closer analysis, it was determined that the most common sites of mutation occur at 
PCS2 and PCS12. To assess the impact of these PCS mutations on viral fitness, we used 
site directed mutagenesis to introduce single amino acid mutations into a fully infectious 
SIV clone (SIVmac239). Ongoing studies include producing virus stocks of the 
SIVmac239 mutants (with multiple PCS mutations) and evaluating the viral fitness of the 
SIVmac239 clones in cell lines using growth competition assays. The data from this 
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study and future studies will help provide information in the areas of vaccine and therapy 
development for HIV. 
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INTRODUCTION 
Human Immunodeficiency Virus (HIV) 
Human immunodeficiency virus (HIV) is a retrovirus that infects and results in 
the destruction of CD4+ T lymphocytes. Left untreated, this CD4+ destruction ultimately 
results in Acquired Immunodeficiency Syndrome (AIDS), due to multiple opportunistic 
infections. In 2013, there were more than 35 million people in the world living with HIV 
1, with the majority of the infected persons from underdeveloped regions in Africa and 
Southeast Asia 2. Two genetically distinct forms of HIV have been found to be present in 
individuals with AIDS: HIV-1 and HIV-2. HIV-1 is the more common form found in 
most patients living with AIDS, while HIV-2 is much less prevalent, as well as of 
reduced pathogenicity. HIV-2 is found predominantly in West Africa 2,3. The global HIV-
1 disease burden, incidence of new infection, and its death toll are shown in Table 1. 
Notably, the number of fatalities due to HIV-1/AIDS has been decreasing due to HIV 
education and antiretroviral treatment 4,5. 
Global Summary of the AIDS Epidemic (2012) 
 
Number of people living 
with HIV 
Total 35.3 million 
Adults 32.1 million 
Women 17.7 million 
Children (<15 years) 3.3 million 
 
People newly infected with 
HIV in 2012 
Total 2.3 million 
Adults 2.0 million 
Children (<15 years) 260,000 
 
AIDS deaths in 2012 
 
Total 1.6 million 
Adults 1.4 million 
Children (<15 years) 210,000 
Table 1. Summary of the number of people living with HIV, the number of newly 
infected people, and the number of deaths due to AIDS in 2012 1 
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However, current treatment methods targeting HIV-1 do not fully eradicate the 
virus 6. The clinically asymptomatic period between HIV-1 acquisition and the first 
clinical symptoms of AIDS can be on the magnitude of years. Once infected, the clinical 
hallmark of HIV is the depletion of CD4+ T cells 7. The course of HIV-1 viremia (as 
measured in the blood plasma) begins with a sharp increase in viral RNA levels, followed 
by a decrease and fairly constant level of viremia, or “set point” during the asymptomatic 
chronic phase. This set point, is a steady state that can be maintained for years and its 
magnitude correlates with both the prognosis and time of progression to AIDS 8. During 
the asymptomatic phase, the total numbers of CD8+ and CD4+ T lymphocytes continues 
to decrease, eventually dropping to a level at which viral replication can no longer be 
controlled. This leads to increased viral loads and progression to AIDS. The course of 
infection is depicted in Figure 1. 
 
Figure 1. Diagram showing the course of HIV infection with changes in CD8+ T 
lymphocytes (blue), CD4+ T lymphocytes (green), and plasma virus load (red) 9 
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Current Treatment Methods 
The current treatment for individuals with HIV-1 is combination antiretroviral 
therapy (cART). cART is currently effective at maintaining an undetectable level of viral 
load of less than 50 copies/mL in infected persons 10. Depending on the class and subtype 
of HIV that a person has been infected with, specific drugs with different mechanisms of 
inhibition can be used: nucleoside reverse transcriptase inhibitors, integrase inhibitors 
and protease inhibitors. Additionally, a drug, nevirapine, a non-nucleoside reverse 
transcriptase inhibitor, is being used to prevent the transmission of all subtypes of HIV 
from mother to child, although its effect is highly variable depending on the subtype of 
the virus 11. Furthermore, integrase inhibitors such as raltegravir or dolutegravir are 
preferred in combination treatment due to their efficacy and lack of severe side effects 12. 
While current therapies may help to manage and control HIV, they are not a cure. 
After prolonged exposure to the antiretroviral drugs or patient non-compliance, the virus 
can quickly mutate and develop resistance to the treatment 13,14. Furthermore, patient 
adherence to the drug is critical for infected persons to maintain undetectable levels of 
viremia. While treatments can help infected persons manage the disease, there are 
negative side effects of the long-term use of cART, ranging from fatigue, nausea and 
vomiting, to more severe symptoms of insulin resistance, pancreatitis and dyslipidemia 
15,16. Until a cure is developed for HIV-1, it is important to find a balance between the 
effectiveness of cART and the long-term drug toxicity and physiological side effects on 
the patient. With the many factors that affect the efficacy and safety of using cART, it is 
increasingly important to develop curative therapies.  
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Experimental Treatment Methods 
Currently, there are ongoing experimental treatments being tested to combat the 
HIV-1. In addition to cART, HIV-specific monoclonal antibodies have been used in an 
attempt to eradicate the disease. Structurally, the Env epitope is very exposed on the 
virus, thus making it a potential target for therapeutic treatments 17. Cocktails of 
antibodies targeting different areas including the CD4 binding site and the N332 glycan 
region on the Env epitope, were used in an attempt to create a broad effect. However, due 
to viral mutations, the effects of these treatments were found to be thwarted after an 
extended period of time 18. However, in a study performed by Diskin et al., broadly 
neutralizing antibodies (bNAbs) were developed that were found to block potential 
pathways for the virus to mutate against the antibodies, which may be a potential route 
for the discovery of a more long term and effective treatment 19.  
 
HIV Dynamics and Viral Load 
To determine the efficacy of treatment methods on eliminating HIV from the 
body, viral dynamics are used to study the relationship between treatment and viral load. 
The viral load of HIV is known as the amount of HIV RNA that is detectable within the 
plasma 20. A major obstacle that challenges scientists in this area is the viral latency 
period of HIV. Once an individual is exposed to the virus, the virus establishes a latent 
reservoir almost immediately after infection. While there are current drugs that can lower 
the viral load of HIV to undetectable levels, those values represent the amount of active 
HIV RNA that is found within the plasma and do not measure the latent reservoir pool 21.  
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Evidence of an early seeding of the viral reservoir before day three of infection 
was shown in rhesus monkeys infected with SIV 22. The discovery of this early 
establishment of the viral reservoir presents a huge challenge in the pursuit of finding a 
cure for HIV. The viral reservoir of SIV was found to be established during the eclipse 
phase between the time of infection and the production of new virions 23. Although there 
was no detectable viremia at the start of ART on day 3, after ART discontinuation, viral 
rebound was observed in all monkeys. With the help of Bayesian statistics, viral dynamic 
models can be created to not only show current effects of a treatment, but also to predict 
future viral loads of HIV over an extended period of time. 
 
HIV Pathogenesis 
When determining how the course of HIV can progress in an infected person, it is 
important to take into consideration each person’s individual genetic makeup. Humans 
can show a combination of six different HLA class I alleles from the three most common 
MHC class I loci HLA-A, HLA-B and HLA-C. The rate of infection and progression to 
AIDS is dependent on which alleles are displayed, representing the different ways the 
host immune system can recognize the virus and destroy it. For example, persons 
displaying alleles HLA-B57, HLA-B27 and HLA-B51 are found to be more likely to 
have long term control of the virus that does not progress to AIDS, while persons with 
HLA-B35 progress rapidly 24. 
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The HIV Replication Cycle 
The first step in the life cycle of HIV begins with the attachment of HIV-1 to the 
host cell. This is carried out by the viral envelope glycoprotein, which begins as a gp160 
molecule and is subsequently cleaved into gp120 and gp41, two necessary molecules for 
proper membrane fusion 25. A specific amino acid sequence on the glycoprotein molecule 
gp120 found on the surface of the viral envelope creates a binding site for the CD4 
surface protein found on various host cells including T lymphocytes, monocytes and 
macrophages 2. The gp120 molecule recognizes one or both of the chemokine receptors, 
CCR5 and CXCR4, which may be expressed on the host cell to attach to the membrane. 
These receptors are responsible for determining which type of cell HIV-1 will infect: The 
CCR5 receptor is found mostly on macrophages, while the CXCR4 receptor is found 
mainly on T cells 26. Any changes to this steps in the mechanism may cause the virus to 
lose the ability to bind to the host cell 27. During the final step of attachment, the viral 
envelope fuses with the host cell membrane with the help of the gp41 molecule 28.  
Similar to other retroviruses, the HIV genome enters the cytoplasm of the host 
cell and becomes incorporated into the host genome with the help of various factors and 
host proteins. Once in the cytoplasm, the reverse transcription complex (RTC), which is 
comprised of the reverse transcriptase, integrase, protease and other accessory proteins 29, 
becomes activated and produces a strand of complementary DNA (cDNA). The cDNA 
then enters the nucleus and becomes incorporated into the genome, where it may remain 
latent for years until it is activated by antigens or cytokines to form infectious viral 
particles 2.  
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The HIV RNA genome is transcribed by cellular RNA polymerase II. New 
particles of HIV are synthesized as three polyproteins that are eventually cleaved to give 
rise to the Gag, Pol and Env genes. The Gag domain consists of the viral core, the Pol 
domain is comprised of the viral enzymes, and the Env domain contains the glycoproteins 
that form the viral envelope 30. Before the cleavage of the polyproteins into mature 
particles, the virus first buds from the host cell. The accessory protein, Vpu, has been 
found to be a necessary factor in helping to promote the budding and release of new viral 
particles 31,32. Once the immature viral particle has been released from the host cell, both 
the Gag and Pol polyproteins must be cleaved in a tightly regulated manner by the HIV 
protease to produce mature, infectious HIV particles 33. Without the proper function of 
the HIV protease, which could be due to mutations within the gene or on the protease 
cleavage sites, the new viral particles formed will not be infectious 34. 
The HIV protease cleaves the Gag polyprotein into the p17 matrix (MA), p24 
capsid (CA), p7 nucleocapsid (NC) and other smaller glycoproteins 35. The production of 
the capsid, a protein made up of two domains, stimulates the maturation process, during 
which a shell is formed around the viral RNA/NC complex and rearranges to form a 
conical core, a core characteristic of an infectious virion. The two domains of the capsid 
are the N-terminal region and the C-terminal domain. The N-terminal domain has been 
found to play a role in viral maturation and the incorporation of cyclophilin A (CypA) 36 
while the C-terminal domain helps with the Gag-gag interactions 35. This Gag-Gag 
interaction plays a role in the communication of cholesterol raft binding that is required at 
the plasma membrane during viral budding 37. 
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Throughout the HIV replication cycle, there are many steps that can be targeted 
by treatment and therapy to halt the replication of and to destroy the virus. These 
different steps are depicted in Figure 2 and include therapy that targets the entry, reverse 
transcription, integration and activity of the HIV protease 28. 
 
Figure 2. Potential steps in the HIV replication cycle that can be targeted for treatment 28 
 
CTL Immune Response and Escape  
 One of the most critical components of the host immune response to HIV 
infection is CD8+ cytotoxic T lymphocyte (CTL) activity. In a study performed by 
Borrow et al., the CTL response towards the HIV envelope protein, gp160, was inversely 
correlated with viral load 38. Furthermore, the inhibition of HIV-1 replication in 
peripheral blood lymphocytes in vitro has been found to be dependent on the presence of 
CD8+ lymphocytes 39. This immune response and control of viral replication is important 
in the development of vaccines and treatments and may play a role in the maintenance of 
suppressed viremia. 
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the search for entry cofactors
 
Because CD4 alone is insufficient to permit the entry
of HIV-1, it has long been suspected that additional
receptors or other factors are required. Although
most HIV-1 isolates successfully infect primary
helper T cells, individual viral isolates have a range
of tropisms (for example, in vitro, some preferen-
tially infect macrophages over T-cell lines) and cause
varying degrees of cell fusion (formation of syncytia
or multinucleated giant cells) in T-cell lines. Amino
acid residues within conserved V3-loop sites of
gp120 were known to affect membrane fusion,
 
12,13
 
but the basis of the differences in tropism was until
recently poorly understood. Important clues to the
“coreceptor” mystery arose from the discovery that
 
b
 
-chemokines (macrophage inflammatory pro-
teins 1
 
a
 
 and 1
 
b
 
 [MIP-1
 
a
 
 and MIP-1
 
b
 
], as well as
RANTES [regulated upon activation normal T-cell
expressed and secreted]), which are chemotactic cy-
tokines produced by macrophages, activated T cells,
and natural killer cells, suppress the replication of
some strains of HIV-1.
 
14
 
chemokine coreceptors (cc chemokine 
receptor 5 and cxc chemokine receptor 4)
 
After the seminal discovery by Feng and colleagues
that a G-protein–coupled chemokine receptor, CXC
chemokine receptor 4 (CXCR4), was the key to cellu-
lar entry for viruses that grow well in cultured T-cell
lines (X4 viruses),
 
15
 
 several groups of researchers
rapidly confirmed that chemokin  rec ptors were
the missing link in our understanding of HIV-1 en-
try (Fig. 2). The expression of CXCR4 made other-
wise impenetrable CD4+ cell lines susceptible to
productive HIV-1 infection. CC chemokine recep-
tor 5 (CCR5), a 
 
b
 
-chemokine receptor with a seven-
transmembrane-protein structure similar to that of
CXCR4, was found to serve as a coreceptor for non–
syncytium-inducing or macrophage-tropic HIV-1
(R5 viruses).
 
16,17
 
 Chemokine receptors are the pri-
mary binding sites for many related retroviruses,
and HIV-1 can be genetically modified to allow CD4-
independent cell entry,
 
18
 
 suggesting that CXCR4
and CCR5 are the primordial receptors, rather than
just cofactors.
 
19
 
HIV-1 isolates of the R5 type have been implicat-
ed in most cases of sexually transmitted HIV infec-
tion, whereas X4 viruses, which replicate best in
T-cell lines, often predominate in the later stages of
HIV disease and may be associated with rapid pro-
gression to AIDS and death.
 
20,21
 
 Clinical isolates
may contain mixtures of R5 and X4 viruses, and
some individual viral strains (R5X4, or dual-trop-
ic viruses) can use either the CXCR4 (X4-virus) or
CCR5 (R5-virus) receptor.
 
22
 
 As previous experi-
ments have suggested, V3-loop amino acid sequenc-
es in gp120 are major determinants of chemokine-
receptor affinity.
 
23,24
 
 Although other chemokine
receptors (CC chemokine receptors 2, 3, and 8,
BOB, and others) can facilitate the entry of specific
HIV-1 variants in vitro, all clinical isolates of HIV-1
use CCR5, CXCR4, or both for entry.
 
25
 
Naturally occurring host defects in CCR5 expres-
sion have demonstrated the clinical significance
of these receptors. A homozygous deletion that
prevents CCR5 expression occurs disproportion-
ately among persons who are frequently exposed to
 
Figure 1. The Life Cycle of Human Immunodeficiency Virus Type 1 (HIV-1), 
Showing Po ential Targets for Antire roviral Therapy.
 
HIV-1 binds to receptors on the cell surface, undergoes membrane fusion, 
and then releases copies of the RNA genome into the cytoplasm. After suc-
cessful invasion of the cell, the viral reverse-transcriptase enzyme transcribes 
single-stranded viral RNA into double-stranded DNA that can be integrated 
into the genetic material of the human host. Reverse-transcriptase inhibitors 
were the first agents approved for the treatment of HIV-1; currently available 
inhibitors of this enzyme are nucleoside antagonists (zidovudine, didano-
sine, zalcitabine, lamivudine, stavudine, abacavir, and combined formula-
tions), nonnucleoside competitive inhibitors (nevirapine, delavirdine, and 
efavirenz), and one nucleotide analogue (tenofovir). The viral integrase en-
zyme is required for the integration of proviral DNA into the host genome 
before replication. Investigational integrase inhibitors are currently in early 
clinical trials. Wh n he infected cell synthesizes ew pr tein, integrated 
proviral DNA is also translated into the protein building blocks of new viral 
progeny. The viral components then assemble on the cell surface and bud out 
as immature viral particles. The final maturation of ewly formed viruses 
requires the HIV-1 protease to digest larger components into the intricate 
pieces that make up an infectious virion. Several protease inhibitors (ritona-
vir, indinavir, nelfi avir, ampren vir, lopinavir–rito avir, and two formulations 
of saquinavir) are currently in clinical use.
Entry inhibitors?
HIV-1
Mature
virus
Reverse-
transcriptase
inhibitors
Integrase
inhibitors?
Protease
inhibitors
The New England Journal of Medicine 
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However, as the virus replicates and persists within the host, it is able to mutate 
and ultimately evade the immune system. As a result, CTLs alone are unable to prevent 
infected patients from succumbing to AIDS. It has been found that the escape variants 
occur by amino-acid replacements within CTL epitopes. In SIV infected rhesus 
macaques, it was shown that changes in the CTL epitopes of Env and Nef genes lead to 
changes in the MHC class I binding and disease progression 40. In a study on rhesus 
macaques performed by Evans et al., different variants in amino acid replacements were 
found, including on the Mamu-A*11 and Mamu-B*03 Env epitope, as well as on the 
Mamu-B*03, Mamu-B*04 and Mamu-B*17 Nef epitopes 41. All these changes resulted 
in a lowered CTL response to SIV infection and pose a major barrier to the development 
of a vaccine for HIV.  
The impact of CTL escape mutations on a population depends on the transmission 
ability of the virus and its stability after transmission. Reversion of an HIV-1 CTL 
epitope mutation after transmission was first observed on the TW10 epitope, which is 
found in a large percentage of the HLA-B57 or HLA-5801 positive population and is the 
immunodominant CTL response in acute infection 42. The escape mutation, T242N, 
found on the TW10 epitope, has been successfully transmitted from persons to persons. 
After transmission of the T242N mutation, the mutation persisted in persons who are 
HLA-B57/HLA-5801 positive (4 of 19 persons during the acute phase of infection), but 
not in persons without the particular alleles (0 of 187 persons), suggesting that the virus 
reverted back to the wild type in the absence of HLA-B57/HLA-5801 43. Reversion of a 
mutation back to its wild type could be due to the associated fitness cost.  
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Determining Viral Fitness 
The fitness of a virus is defined as its ability to adapt to the environment and 
continue to replicate and produce infectious copies of itself 44. Mutations within the viral 
genome will inevitably occur due to natural selection as the virus undergoes various 
changes towards selective pressures such as the development of drug resistances to 
reverse transcriptase and protease inhibitors, fusion inhibitors and CCR5 inhibitors. In a 
study performed by Anastassopoulou et al., fitness was defined as the ability of the HIV 
strain to replicate in tissue cultures. The viral fitness of HIV after developing resistance 
to a CCR5 inhibitor drug, AD101, was examined by using a comparative fitness analysis. 
Using a dual-infection growth competition assay, a resistance to AD101 which occurs by 
a change in four amino acids within the V3 region of gp120, showed no changes viral 
fitness and did not lead to a fitness loss 45. Understanding viral behavior towards 
treatment drugs and how its fitness changes in response can play a vital role in the 
development of a cure for HIV.  
 
Using the Simian Immunodeficiency Virus as a Model 
The best model to date for the study of HIV and the development of a vaccine has 
been the non-human primate (NHP) and the simian immunodeficiency virus (SIV) 
system. There are a number of key features that the model must display 46. The model has 
many features that recapitulate HIV/AIDS in humans: 
1. Demonstrate persistent, progressive systemic infection after inoculation 
2. Use the CCR5 co-receptor for infection 
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3. Undergo acute depletion of memory CD4+ T cells, specifically from mucosal 
sites 
4. Establish an initially disease-free plateau phase 
5. Show progression to AIDS over a period of several months to years 
The simian immunodeficiency virus from macaques, previously known as simian T-cell 
lymphotropic virus type III (STLV-III), is related to HIV in humans in many ways, 
including by its antigenicity, morphologic and growth properties 47,48. These similarities 
make it the best model for studying HIV.  
Furthermore, after SIV infection, the progression of the virus is very similar to 
that of HIV in humans. There is an extremely high rate of infection and a rapid 
destruction of memory CD4+ T cells. At the peak level of SIV infection of rhesus 
macaques, approximately 30-60% of all memory CD4+ T cells become infected and at 
four days post-peak infection, about 80% of the infected cells are destroyed 49.  
 
Current Investigation and Specific Aims 
As HIV and AIDS continue to infect and kill people worldwide, it is increasingly 
important to find and develop a full eradication strategy targeted against the virus. 
Targeting the HIV protease as a mechanism for stopping HIV replication is a potential 
avenue in vaccine development. Altering the function of HIV protease leads to the 
production of immature, noninfectious viral particles, thus halting the replication of HIV. 
The HIV protease is required by the virus to process the polyproteins Gag and Gag/Pol, 
which are necessary for complete replication within a host cell 50,51. The HIV protease 
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functions by identifying cleavage sites on the proteolytic precursors Pr55 for Gag and 
Pr160 for Gag/Pol. Using an in vitro HIV protease assay, Kohl et al. determined that a 
single mutation that caused an amino acid change at position 25 on HIV protease from 
aspartate to asparagine rendered the HIV protease to become nonfunctional. This 
alteration stopped the ability of HIV protease to cleave HIV gag p55 to gag p24 and gag 
p17 52. Without proper identification, the tightly regulated normal processing function 
and rate of cleavage by the protease can be lost. Factors that may alter the processing and 
cleavage include the sequence, structure and availability of the cleavage site to the HIV 
protease 53.  
Previous studies have been carried out to determine the effect of protease 
inhibitors on HIV. A study was performed and analyzed the infectivity of viral particles 
produced in the presence of protease inhibitor and viral particles produced from proviral 
plasmids with mutations to its cleavage sites. It was found that even low concentrations 
of a protease inhibitor caused a small, but effective enough change on the polyprotein 
processing of Gag that it led to a decreased production of infectious viral particles 54.  
The aim of this project is to investigate the use of HIV’s protease cleavage sites 
(PCS) in the development of a vaccine that can be used as a cure for infected individuals, 
as well as to prevent future infections. The results that have been shown in this thesis 
were generated in Dr. Ma Luo’s laboratory in the University of Manitoba, as part of an 
ongoing collaboration. The data were analyzed and discussed in collaboration with Dr. 
Whitney’s laboratory at the Beth Israel Deaconess Medical Center as a part of an HIV 
vaccine development consortium. Using the previously obtained data (unpublished data 
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from Luo et al.), we were able to determine immune correlates, single mutations and 
interacting mutations, which allowed us to better develop the basis for beginning this 
specific phase of the project of creating SIV clones. The protease cleavage sites of 
interest for this project are sites 2 and 12, which are located on the p2 Gag spacer and Nef 
protein, respectively. Viruses with the mutants will be synthesized using site directed 
mutagenesis, and their fitness will be evaluated by growth competition assays. These 
experiments will be carried out using the SIV model. 
 
	  14 
METHODS 
Animals, SIV Challenge and Vaccination Protocol 
This study enrolled and monitored 17 adult Cynomolgus macaques (Macaca 
fascicularis). All animals were genotyped for their MHC haplotypes by both PCR and 
MHC-amplicon sequencing. The monkeys were housed under biosafety level-2+ 
conditions, and were routinely monitored by physical examination and T cell subset 
analysis before and after SIV infection.  
 
Specimen Collection and Processing  
Peripheral blood was collected weekly from each monkey. The PBMC’s were 
separated on Ficoll-Hypaque cushions following standard protocols. All PBMC cultures 
were first purified by CD8 depletion using a commercial MACS magnetic bead depletion 
assay (Miltenyibiotec Inc.) and then cyropreserved and frozen at –180 ºC for later use. 
After thawing, all PBMC were stimulated for 48 hours with Concanavalin A, prior to use 
in experiments. The PBMC’s were maintained in a lymphocyte medium (RPMI 1640 
with 10% FBS and 40 U/mL IL-2). Blood plasma was immediately frozen and 
maintained at –80 ºC until use. 
 
Viral RNA Extraction and qRT-PCR Detection   
Viral RNA was routinely isolated from 140 µL of blood plasma using the 
QIAamp Viral RNA Mini Kit (Qiagen) following the manufacturer’s protocol. RNA 
recovered from spin columns was eluted into a final volume of 60 µL. 
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cDNA Synthesis   
A 10 µL volume of extracted RNA was reverse transcribed to single-stranded 
cDNA as described by the manufacturer in the Superscript III protocol (Invitrogen). The 
RNA, deoxynucleotides (0.5 mM each), and 0.24 µM primer OR9608 (5’ – 
CTCATCTGATACATTTACGGGG – 3’) were then incubated for 5 minutes at 65 ºC. 
The sample was then chilled on ice for 1 minute, followed by a brief centrifugation. The 
first strand of the cDNA synthesis was completed by the addition of 10 µL of 5x reaction 
buffer, 2.5 µL of 0.1 M DTT, 2.5 µL of RNase Out, and 2.5 µL of Superscript III RT to 
the sample. The mixture was incubated as follows: 60 minutes at 50 ºC, 60 minutes at 55 
ºC and 15 minutes at 70 ºC.  Finally, 5 units of RNase H were added and the mixture was 
incubated for 20 minutes at 37 ºC. 
 
QPCR assay 
The SIV RNA standard was transcribed from the pSP72 vector containing the first 
731 base pairs of the SIVmac239-Gag gene using the Megascript T7 kit (Ambion Inc., 
Austin, TX). RNA was isolated by phenol-chloroform purification followed by ethanol 
precipitation. All purified RNA preparations were quantified by optical density and the 
RNA quality was determined by the Agilent bioanalyzer RNA chip (Agilent Santa, Clara 
CA).  
Quantitative RT-PCR was conducted in a 2-step process. First, RNA was reverse 
transcribed in parallel with an SIV-gag RNA standard using the gene-specific primer s-
Gag-R: 5’CACTAGGTGTCTCTGCACTATCTGTTTTG-3’). Each 50 µL reaction 
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contained 1X buffer (250 mM Tris-HCL pH 8.3, 375 mM KCl, 15 mM MgCl2), 0.25 µM 
primer, 0.5 mM dNTPs (Roche), 5 mM dTT, 500 U Superscript III RTase (Invitrogen, 
Carlsbad, CA), 100 U RnaseOUT (Invitrogen, Carlsbad, CA), and 10 µL of sample. The 
PCR conditions used were as follows: 1 hour at 50 ˚C, 1 hour at 55 ˚C and 15 minutes at 
70 ˚C. All samples were then treated with RNAse H (Stratagene, Cedar Creek, TX) for 20 
minutes at 37 ˚C. All real-time PCR reactions used EZ RT PCR Core Reagents (Applied 
Biosystems, Foster City, CA) following the manufacturer’s suggested instructions under 
the following conditions: the 50µL reactions contained 1X buffer (250 mM Bicine, 575 
mM potassium acetate, 0.05 mM EDTA, 300 nM Passive Reference 1, 40% (w/v) 
glycerol, pH 8.2, 0.3 mM each of dATP, dCTP, dGTP, 0.6 mM dUTP, 3 mM Mn (OAc)2, 
0.5 U uracil N-glycosylase, 5 U rTth DNA Polymerase, 0.4 uM of each primer, and 10µL 
of sample template. PCR reagents were assembled at room temperature (RT) and spun 
briefly to eliminate air bubbles.  Following 2 minutes at 50 ˚C, the polymerase was 
activated for 10 minutes at 95 ˚C, and then cycling proceeded at 15 seconds at 95 ˚C and 
1 minute at 60 ˚C for fifty cycles. Primer sequences were adapted from those described 
by 55, forward primer s-Gag-F: 5’-GTCTGCGTCATCTGGTGCATTC-3’, reverse primer 
s-Gag-R: 5’-CACTAGGTGTCTCTGCACTATCTGTTTTG-3’, and the probe s-Gag-P: 
5’-CTTCCTCAGTGTGTTTCACTTTCTCTTCTGCG-3’, linked to Fam and BHQ 
(Invitrogen, Carlsbad, CA). All reactions were carried out on a 7300 ABI Real-Time PCR 
system (Applied Biosystems) in triplicate according to the manufacturer’s protocols. 
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Construction of PCS mutant SIV clones  
Two mutated SIV clones were created: SIV-PCS2-mtracking vector and SIV-
PCS12-mtracking vector. The first step in the construction of the mutated SIV-PCS2- 
mtracking vector, SIV-PCS2-m, involved subcloning of the region located between 
restriction sites BamHI (position 2104) and SphI (position 6701) from the full-length 
infectious clone of SIVmac239, derived from a biological isolate of SIVmac251, as 
described by Whitney et al.56 into pSP73 (Promega). The first step in the construction of 
the mutated SIV-PCS12- m-tracking vector, SIV-PCS12- m, involved subcloning of the 
region located between restriction sites SphI (position 6701) and XhoI (position 10535) 
from the full-length infectious clone of SIVmac239, derived from a biological isolate of 
SIVmac251, as described by Whitney et al., into pSP73 (Promega). The resulting plasmid 
was subjected to site-directed mutagenesis to insert 3 and 2 nonsynonmous mutations into 
the PCS2 or PCS12 region, respectively, using the Stratagene Quickchange I kit, as 
specified by the manufacturer. The mutagenized BamHI-SphI fragment and the SphI-
XhoI fragment were then inserted into the parental clone to produce the PCS2-mutant 
(PCS2-M) and PCS12-mutatnt (PCS12-M) clones, respectively. Infectious virus stocks 
were prepared by transient transfection of 293T cells with SIVmac239 wild type or 
PCS2/12-M plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to 
the manufacturer's instructions. 
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Virus stocks  
Viruses used in the fitness studies are both biological isolates and chimeric virus 
derived from the vaccine and control arms of a primate-based HIV-candidate vaccine 
study 57. Stocks of each isolates were prepared. All infectious stocks were stored in 
aliquots at -80 °C. The titers 50% tissue culture infectious dose (TCID50) of all stocks 
were determined in PBMC culture by standard methods and data was analyzed using the 
method described by Spearman and Karber 58. 
 
Growth-Competition Assays 
Growth competition assays will be performed in 12-well plates seeded with 2e 106 
PHA-activated rhesus PBMC’s in 2 mL of total volume. The two viruses under 
evaluation are added to the target cells at individual MOI of 0.001 or 0.005, which are 
generally accepted to be low enough to prevent recombination. To limit the inherent 
variability of PBMC replication assays, each data point is derived from duplicate cultures 
on the same plate, and all experiments will be performed twice. Competition cultures 
involving viruses will be maintained for 14 days and supernatants are taken at days 3, 5, 
7, 9 and 12. PBMC’s will be harvested, washed twice with phosphate-buffered saline 
(PBS), and pelleted for DNA extraction using the QIAamp DNA Blood Mini Kit, 
according to the manufacturer's protocol. Virus production in culture fluids are monitored 
by both RT-PCR and SIV p27 antigen capture assay (Coulter Immunotech Inc., 
Westbrook, ME, U.S.A.). 
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Single Genome Amplification of SIV Envelope   
Viral cDNA is diluted in 96-well plates to yield fewer than 30% of positive wells 
for amplification to ensure that positive amplifications are a result of a single cDNA 
59.The first round of PCR is carried out in a reaction mixture containing the following: 1X 
buffer (Platinum Taq HF Kit, Invitrogen), 0.2 mM dNTP mix, 2 mM Mg2SO4, 0.2 µM 
primer OF6207 (5’ – GGGTAGTGGAGGTTCTGGAAG – 3’), 0.2 µM primer OR9608 
(5’ – CTCATCTGATACATTTACGGGG – 3’), and 0.025 units of Platinum Taq High 
Fidelity polymerase to give a total volume of 20 µL for each reaction. The PCR mixtures 
are then loaded into MicroAmp Optical 96-Well Reaction Plates (Applied Biosciences) 
and the conditions for the first round of PCR are programmed as follows: 5 minutes at 94 
ºC, 35 cycles of 15 seconds at 94 ºC, 30 seconds at 52 ºC, and 4 minutes and 15 seconds 
at 68 ºC, followed by a final extension time of 10 minutes at 68 ºC. For the second round 
of PCR, 2 µL of the first round PCR product was mixed with 1X buffer (Platinum Taq 
HF Kit, Invitrogen), 0.2 mM dNTP mix, 2 mM Mg2SO4, 0.3 µM primer IF6428 (5’ – 
CGTGCTATAACACATGCTATTG – 3’), 0.3 µM primer IR9351 (5’ – 
CCCTACCAAGTCATCATCTTC – 3’), and 0.025 units of Platinum Taq High Fidelity 
polymerase to give a total volume of 20 µL for each reaction. The PCR conditions for the 
second round are programmed as follows: 5 minutes at 94 ºC, 45 cycles of 15 seconds at 
94 ºC, 30 seconds at 51 ºC, and 3 minutes and 30 seconds at 68 ºC, followed by a final 
extension time of 10 minutes at 68 ºC. The amplicons from the cDNA dilutions that 
resulted in less than 30% positive reactions will be sequenced at the Dana-Farber/Harvard 
Cancer Center DNA Resource Core. Eight sequencing primers spanning the length of the 
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SIV envelope are used for complete envelope sequencing. For each monkey, between15-
30 SIV envelope sequences are analyzed per time point. 
 
SIV Envelope Sequence Analysis   
Raw sequencing data will be analyzed utilizing the GeneCodes Sequencher 4.8 
DNA sequencing software.  Groups of primer sequence fragments are assembled into 
overlapping contigs utilizing Sequencher’s automatic assembly algorithm. 
Chromatograms of assembled contigs will be reviewed and manually corrected for all 
ambiguous bases. 
 
Bioinformatic Analysis: Alignments and Phylogenetic Analysis 
Edited contig consensus sequences will be exported to the Los Alamos National 
Laboratory (LANL) for translation. The HIV sequence database translate tool 
(http://www.hiv.lanl.gov) is also used for further bioinformatic analysis. Nucleotide and 
translated contig consensus sequences are aligned with the online database EBI Tools 
ClustalW 60 under default conditions. When necessary, nucleotide alignments are 
manually aligned using the BioEdit Sequence Alignment Editor program to prepare them 
for phylogenetic analysis. 
Edited sequences will also be sent to Dr. Bette Korber of the Los Alamos 
National Laboratory for phylogenetic analysis. All phylogenetic analysis of nucleotide 
sequences will be performed using the MEGA 4 evolutionary analysis software package. 
Evolutionary trees are inferred using the maximum parsimony and neighbor-joining 
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methods. The bootstrap consensus trees are inferred from 500 replicates and are taken to 
represent the evolutionary history of all taxa analyzed.  Maximum parsimony trees will 
be obtained using the Close-Neighbor-Interchange method in which the initial trees are 
obtained with the random addition of sequences (10 replicates). All positions containing 
gaps and missing data will be eliminated from the datasets. 
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RESULTS 
Vaccine targeting of PCS controls SIV in Cynomolgus macaques following experimental 
challenge with SIV. 
As classical vaccine approaches to elicit either T cell or antibody responses 
against HIV-1 have so far produced no or modest effects, new approaches are 
necessitated. The immunogenicity of the sequences around the protease cleavage sites 
(PCS) and the population coverage for a vaccine targeting HIV-1 PCS has been 
investigated61. In the pilot study, sequences around PCS were assessed as targets for the 
development of a new vaccine strategy using Cynomolgus macaques from the Philippines 
and SIVmac239 as an experimental model. The regimens have included vaccine 
immunogens that are cocktails of 20mer peptides overlapping the 12-protease cleavage 
sites (PCS). 
Both plasma SIV RNA levels and CD4+ T cell counts were monitored in this 
cohort of cynomolgus monkeys through 20 weeks after SIVmac239 challenge. Plasma 
virus RNA levels looked similar between the vaccine and control group, and this 
observation is mostly due to higher dose of SIVmac239 used to infect the vaccine group 
(Figure 3A). Despite there being no obvious differences in the plasma virus RNA level 
between the vaccine and control groups, a comparison of the total numbers of CD4+ T 
cells between two groups showed that the vaccinated group maintained higher CD4+ 
counts. In the vaccine group, 6 out of 11 animals were able to maintain their CD4+ T cell 
levels until the end point of the study, while 4 of the 5 monkeys in the control group 
showed a decline in CD4+ T cell count during the progression of the study (Figure 3B, 
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Table 2).  This maintenance of CD4+ T cells indicates that the virus was not successful 
in continuing to destroy the immune system via killing the CD4+ T cells. It shows that 
the vaccine might have produced a specific immune pressure to generate a mutation that 
makes the virus less fit and renders it unable to reproduce infectious particles. 
 
A        B 
 
 
Figure 3. The kinetics of plasma SIV RNA and total CD4+ T cell counts following 
SIVmac239 infection. (A) Plasma virus RNA levels were assessed in cynomolgus 
monkeys between weeks 1 to 20 after challenging with SIVmac239. Log10 SIV RNA 
copies/mL for each monkey in both the vaccine (red) and control (blue) groups are 
shown. Median viral loads in both the vaccine (black solid) and control (black dashed) 
groups are also shown. (B) Changes in CD4+ T cell counts for each monkey in both the 
vaccine (red) and control (blue) groups over time were plotted. Changes in the number of 
CD4+ T cell counts (ΔCD4+ T cells) were calculated by subtracting the absolute CD4+ T 
cell counts of the following week from those of the previous week. 
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 Vaccine (n=11) Control (n=5) 
Weeks after 
infection 
# of animals with 
CD4 decline (%) 
# of animals with 
CD4 maintain (%) 
# of animals with 
CD4 decline (%) 
# of animals with 
CD4 maintain (%) 
MID11 5 (45) 6 (56) 3 (60) 2 (40) 
MID13 4 (36) 7 (64) 4 (80) 1 (20) 
MID14 7 (64) 4 (36) 4 (80) 1 (20) 
Endpoint 5 (45) 6 (56) 4 (80) 1 (20) 
 
Table 2. Change in total CD4+ T cell counts in Cynomolgus macaques following 
infection Monkeys in the cohort are shown in 2 groups: one group of animals that showed 
a decline in total CD4+ T cell counts and the other group of animals that maintained 
CD4+ T cell counts. 
 
This vaccine modality was also found to generate antibody and T cell responses in 
the macaques. The antibody response to the peptides overlapping the PCS is correlated 
with a reduction in viral load during the acute phase of SIV infection, while long-term 
durable control during the chronic stages, for example the set-point, is less pronounced 
(Figure 4A, 4B). Furthermore, vaccine-elicited control of viral load was maintained over 
the course of 20 weeks post-challenge, which is shown by significant associations 
between the vaccine elicited antibody response and an area-under-the curve calculation 
for the plasma SIV RNA levels between week 1 and 20 following infection (Figure 4C, 
Table 3).  
 
 
 
 
 
 
 
	  25 
 
 
A       B 
  
C 
 
 
 
 
Figure 4. Correlation between vaccine-induced immune responses and plasma SIV RNA 
levels in the vaccine group. Correlation matrices were generated using the Spearman 
nonparametric correlation to compute the correlation coefficients for each pair of 
variables including plasma antibody and Elispot responses to the number of PCS peptides 
and plasma SIV RNA levels in the vaccine group. The plasma SIV RNA levels were 
assessed on 2-4 weeks and 9-14 weeks following challenge, representing peak (A) and set 
point (B) viral load, respectively. Area-under-the curve calculations (C) for the plasma 
SIV RNA levels were also assessed in these monkeys.  
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 Peak Set-point AUC 
 
1Rho (ρ) 2P value 1Rho (ρ) 2P value 1Rho (ρ) 2P value 
Plasma antibody to 
No. Of PCS peptides -0.63 0.03 -0.02 0.94 -0.63 0.03 
Elispot response to No. 
Of PCS peptides 0.30 0.37 0.03 0.92 0.06 0.84 
Total -0.41 0.19 -0.14 0.67 -0.56 0.06 
 
Table 3. Correlation between vaccine-induced immune responses and plasma viral load 
in the vaccine group. 1) The Spearman correlation coefficients (ρ) are shown. 
2) Exact P values for nonparametric Spearman correlation are also shown. 
 
 Amino acid mutations in sequences around the PCS sites and correlations with plasma 
virus RNA levels  
Figure 5 shows the locations of the twelve protease cleavage sites located at 
specific locations across the HIV-1 genome. Five cleavage sites are found on the 
Pr55Gag protein, six cleavage sites are found on the GagPol protein, and one cleavage 
site is found on the Nef protein. 
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Figure 5.  A schematic diagram illustrating landmarks of the HIV-1 genome and its 12 
proteolytic cleavage sites. Twelve unique cleavage sites between Gag, Gag-Pol and Nef 
precursor polyproteins are designated. 
 
Viral sequence analysis revealed extensive mutations around PCS regions in both 
vaccinated and control monkeys over 20 weeks after infection (Figure 6). Comparisons 
of the PCS mutation frequencies were conducted at each time point between the vaccine 
and control groups. Evaluations of the percentage of PCS mutation were carried out using 
data during the MID periods. Two out of the twelve cleavage sites, PCS2 and PCS12, 
were found to have amino acid mutation frequencies of greater than 10% in response to 
the vaccine treatment. Figure 7 depicts the percentage of each mutation found on PCS2 
and PCS12. Specifically, virus recovered from the vaccine group showed significantly 
higher frequencies of mutation in PCS12 region (P=0.009), which corresponds to a 
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change from glycine to either arginine or glutamic acid compared to the mutation 
frequencies in the control group. Amino acid mutation in PCS2 (-8) was associated with 
moderate yet significant increase of viral replication. However, amino acid mutation in 
PCS12 (-8) displayed a negative correlation with the plasma viral load (Figure 8). At the 
time-points when the frequency of the PCS mutation got greater, the plasma viral load 
was lower compared to the plasma viral load at the time-points when the PCS mutation 
frequencies are lower. 
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B 
 
Figure 6. The major PCS amino acid mutations of plasma SIVmac239 in a cohort of 
monkeys. The frequencies of each PCS amino acid mutation following infection with 
SIVmac239 in the vaccine (A) and control (B) groups are shown in various colored solid 
lines and corresponding plasma SIV RNA copies are shown in the black solid line. 
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Figure 7. Comparison of the major PCS amino acid mutation frequencies 
between the vaccine and control groups. The total sum of frequencies found in the major 
PCS were compared. The amino acid encoded by wild type SIVmac239 (black) precedes 
the dash, which is followed by the amino acid encoded by the mutation (red).  The 
comparison of the values from the groups of animals was determined using a non-
parametric one-way ANOVA Kruskal-Wallis test with Dunn's multiple comparison test 
or the Mann-Whitney test. The amino acid mutations less than 10% in other PCS sites 
were not included in the analysis. 
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Figure 8. Correlation between the major PCS amino acid mutation and plasma viral load 
in the vaccine group. Correlation matrices were generated using Spearman nonparametric 
correlation to compute the correlation coefficient for each pair of variables including PCS 
amino acid mutations (PCS2: -8, -7, and -6 and PCS12: -8) and plasma SIV RNA levels 
in the vaccine group. 
 
Construction of major PCS amino acid mutations 
To introduce point mutations into each PCS region, the fragment between the 
BamHI and SphI sites, and the SphI and XhoI was subcloned into the pSP73 vector to 
generate a clone termed pSP73-PCS2, and the fragment between the SphI and XhoI sites 
was subcloned into the pSP73 vector to generate the clone termed pSP73-PCS12 (Figure 
9A). The Quick Change site-directed mutagenesis kit (Stratagene, La Jolla, Calif.) was 
used to introduce PCS2 (-8, -7 and -6) and PCS12 (-8) point mutations procedures 
described by manufacturer (Figure 9B). The presence of all point mutations was 
confirmed by direct sequencing (Figure 9C). The BamHI-SphI fragment was cloned 
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back into SIVmac239 to generate the SIVmac239-PCS2 mutant clones; the SphI-XhoI 
fragment was cloned into the SIVmac239 to generate both SIVmac239-PCS12 (-8R) and 
SIVmac239-PCS12 (-8E) clones (Figure 9D). All SIVmac239 PCS mutants generated in 
the study are listed in Table 4.  
Infectious virus stocks were prepared by transient transfection of 293T cells with 
SIVmac239 wild type or each PCS mutant plasmid as described above using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's 
instructions. 
 
A 
SIVmac239      pSP73     Ligation            
                      pSP73-PCS2 
       
                              pSP73-PCS12 
 
B 
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C 
 
 
D 
 
 
Figure 9. Construction of major PCS amino acid mutation. (A) Digestion of both 
SIVmac239 and pSP73 vector with BamHI and SphI or SphI and XhoI followed by 
ligation using T4 DNA ligase to create pSP73-PCS2 and pSP73-PCS12, respectively. (B) 
Site-directed mutagenesis strategy to create the point mutations. (C) Sequencing 
alignments to confirm the successful introduction of each individual mutant into the 5 
SIVmac239. A) PCS2-8, B) PCS2-7, C) PCS2-6, D) PCS12-8E, E) PCS12-8R. (D) Full 
length SIVmac239 PCS mutant clones. 
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 PCS2 PCS12 
 -8 -7 -6 -8 
SIVmac239-WT P G Q G 
SIVmac239-PCS2(-8) R G Q G 
SIVmac239-PCS2(-7) P D Q G 
SIVmac239-PCS2(-6) P G E G 
SIVmac239-PCS12(-8R) P G Q R 
SIVmac239-PCS12(-8E) P G Q E 
SIVmac239-PCS2(-8)/PCS12(-8R) R G Q R 
SIVmac239-PCS2(-7)/PCS12(-8R) P D Q R 
SIVmac239-PCS2(-6)/PCS12(-8R) P G E R 
SIVmac239-PCS2(-8)/PCS12(-8E) R G Q E 
SIVmac239-PCS2(-7)/PCS12(-8E) P D Q E 
SIVmac239-PCS2(-6)/PCS12(-8E) P G E E 
Table 4. SIVmac239 PCS region mutant clones generated in the current study and the 
major amino acid mutation in PCS region. The amino acids encoded by wild type 
SIVmac239 are shown in black and the amino acid mutations generated as described in 
materials and methods are shown in red.  
Future Work - Competitive Fitness Assay 
To continue the evaluation of the PCS vaccine on SIVmac239 fitness, competitive 
fitness assays should be carried out as shown in Figure 10 and Figure 11. The details of 
how the experiments will be conducted are also described under the Methods section. 
Due to the highly frequent mutations that occur in SIV, it is important to understand how 
a mutation at a critical site can affect a virus’s ability to replicate and survive. To design a 
viral fitness assay, many factors must be taken into account (Figure 10).  
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A typical set up for a growth competition experiment is displayed in Figure 11. 
The experiment involves dual infections with a control virus, commonly the wild-type 
virus, and an experimental virus, for example, a mutated virus. The infections are carried 
out with different multiplicities of infection and are compared to the positive controls 
(wells I, V) and the negative control (well VI) 62. Depending on the fitness of the two 
viruses in the study, one may be selected over the other indicating a greater fitness and 
likelihood of survival.  
 
Figure 10. Practical considerations in the design of a competitive viral fitness assay.  
Schematic representation of each of 5 aspect to be considered in the selection of them 
most appropriate assay conditions including Culture environment 1, Virus isolate 2, 
Inoculum titration 3, Assay specifics 4, and Experimental endpoints 5. (Adapted from 
Quinones-Mateau and Arts 2006)63. 
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Figure 11. General setup of a virus competition assay. Fitness (W) can be calculated by 
the proportion of virus in a dual infection (fo ) divided by its initial level in the inoculum 
(io). The relative fitness difference (Wdiff) can be determined by the ratio of the more fit 
(WM) and less fit (WL) virus. (Figure adapted from Quinones-Mateau and Arts, 2000)62. 
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DISCUSSION 
The advent of potent combination antiretroviral therapy (cART) has dramatically 
improved the quality of life and life expectancy of millions of HIV-infected individuals.  
HIV-1 infected patients could maintain near undetectable levels of viremia, if they have 
access to these medications and are motivated to take them daily for life.  However, as 
antiretroviral drugs could not eradicate a stable latent reservoir in resting CD4+ memory 
cells that harbors virus that are refractory to antiretroviral drugs and HIV specific 
immune responses, providing a long-term archive of replication-competent virus. 
Moreover, even for every individual who gains access antiretroviral drugs, two to three 
individuals become newly infected. Thus, efforts to reduce or eradicate HIV reservoir are 
now centered on a new strategy aimed perturbation of the virus reservoir, followed by 
rapid removal of infected cells 64. To augment the capacity of the host to eliminate 
latently infected cells after activation by latency-reversing agents, several immunologic 
strategies have been explored including 1) therapeutic vaccines, 2) monoclonal 
antibodies, and 3) inhibitors of immune check point molecules such as PD-1, CTLA-4, 
LAG-3 and TIM-3. 
With the goal of eliciting virus-specific immune responses, a safe, effective and 
affordable vaccine is highly needed to counter the tide of new infections (i.e. 
prophylactic), accelerate the decay of the reservoir and improve the control of viral 
rebound after the interruption of cART (i.e. therapeutic). Unfortunately, the classical 
vaccine approach to elicit either T cell or antibody responses against HIV-1 has failed so 
far or produced a modest effect.  Several novel vaccines have currently been explored or 
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are being evaluated in clinical trials within the next several years. Among such strategies 
including CMV vectors, AD26 prime and modified vaccinia Ankara (MVA) boost 
regimens, CMV vectors led to induce broad cellular immune responses and apparent 
clearance of SIV in about 50% of vaccinated monkeys 65,66. 
The recent study showed that the sequences around the PCS are very 
immunogenic and could be viable vaccine targets 61.  HIV-1 protease has been the major 
therapeutic target against AIDS due to its essential role in the production of infectious 
virions. The process of protease cleavage requires a tightly controlled, ordered sequence 
of proteolytic processing events mediated by different rates of cleavage at the different 
processing sites. Even the subtle disturbances may be sufficient to interrupt this delicately 
balanced process and drive it toward producing non-productive virions. Therefore, 
vaccine targets the 12 protease cleavage sites would yield major advantages as these 
cleavage sites are highly conserved among major subtypes of HIV-1. To test this 
hypothesis, preclinical animal studies has been conducted to test whether a vaccine 
generating focused immune responses to the 12 20-amino acid peptides overlapping the 
12 protease cleavage sites can offer protection against HIV infection. 
 The preliminary data from the preclinical animal studies showed that two 
cleavage sites among 12 PCS, PCS2 and PCS12, have shown amino acid mutation 
frequencies greater than 10 % in the vaccine group. Mutations at protease cleavage sites 
might occur due to immunologic pressures induced by the vaccine as described above. 
Specifically, higher frequencies of mutation in PCS12 region found in the vaccine group 
were significantly correlated with the lower plasma viral RNA levels. Amino acid 
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mutation in PCS2 (-8) was associated with moderate yet significant increase of viral 
replication. However, to correlate these virologic measurements with the protection of 
12-PCS vaccine, whether these mutations change viral fitness and its infectivity is yet to 
be determined. Experiments were designed and conducted to determine the virologic 
correlates of such protection of a PCS based vaccine using viral fitness analysis of major 
PCS mutations in SIVmac239 in vitro. We were able to construct SIVmac239 clones with 
five single amino acid mutation found in PCS2 (-8, -7 and -6) and PCS12 (-8) regions.  
When determining how to construct the SIVmac239 clones, it was important to 
choose restriction enzymes that only had a single cut location. These enzymes should 
cleave both the plasmid vector and the full-length virus at specific locations to isolate the 
PCS2 and PCS12 areas. During the initial construction, the restriction enzymes were not 
correctly chosen and as a result, transformation of the SIVmac239 clones into competent 
cells was unsuccessful. The first set of enzymes used to construct the PCS2 and PCS12 
mutants consisted of EcoRI + SspI and ClaI + XhoI, respectively. However, it was 
discovered that both EcoRI and ClaI recognize multiple cut site on the SIVmac239 
backbone and within the insert. We re-analyzed the restriction map for both SIVmac239 
and the plasmid vector pSP73 and determined that the combination of restriction enzymes 
that should be used were BamHI + SphI and SphI + XhoI for PCS2 and PCS12, 
respectively. 
Further studies will include SIVmac239 clones with multiple permutations to 
further investigate the effects of how altering the HIV protease cleaving mechanism can 
aid in destroying the virus’s ability to survive. This information will provide important 
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information to aid the development of an effective preventative HIV-1 vaccine targeting 
PCS regions. 
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• Helped run functional magnetic resonance imagining tests on participants to 
evaluate the responses to tactile stimuli of vibration intensity and timing 
 
OTHER WORK EXPERIENCE         
 
Beantown Physio, Inc., Boston, MA | August 2014 – present 
Front Desk Coordinator 
• Serve as the first contact point to meet and greet patients in the office 
• Perform administrative duties including scheduling appointments, contacting 
insurance companies and balancing payments 
 
LEADERSHIP EXPERIENCE         
 
Georgia Tech Women’s Ultimate Frisbee Club Team | August 2009 – May 2012 
President 
• Communicated with the Georgia Tech Sports Club director and the Student 
Government Association to ensure details of practice, travel, and funding were 
kept up with in an organized manner  
• Discussed with the coaches and other college ultimate teams in the Southeast to 
decide and choose which tournaments to attend during the season 
 
Georgia Tech Trailblazers 
Secretary and Treasurer | May 2009 – May 2010 
• Organized and took meeting minutes 
• Was responsible for the financial duties of the organization  
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Vice President of Alternative Breaks and Trip Leader | May 2010 – May 2012 
• In charge of overseeing the planning of all fall and spring alternative break trips 
• Worked closely with not only other members on the alternative breaks committee, 
but also members from the National Park and Forest Services to plan 
environmental awareness and community service trips 
• Planned and led two alternative break trips to Virginia and South Carolina 
 
Vice President of Local Projects | May 2011 – May 2012 
• Managed a team of four local project committee members and planned monthly 
trips to help give back to the environment and community in and around the 
Atlanta/North Georgia area 
 
Georgia Tech Honors Program Planning Committee | May 2009 – October 2009  
Fall Retreat Planning Committee  
• Helped to organize the annual GT Honors Program fall retreat for incoming 
freshman at a local state park in Georgia.  
 
VOLUNTEER EXPERIENCE          
 
Rosie’s Place, Boston, MA | January 2013 – present  
• Serve as a volunteer in the dining room/kitchen or in the food pantry to assist and 
provide help to homeless women and children in the Boston area 
 
Georgia Tech Alumni Association, Boston, MA | October 2014 – present 
Boston Network, Philanthropy Chair 
• Organized community service events for the Georgia Tech Alumni Association, 
including the 2014 TEAM Buzz event with The Food Project, a local urban farm, 
and the Annual Earth Day Charles River Clean Up 
 
Camp Braveheart, Camp Twin Lakes, Atlanta, GA | May 25-31, 2013 
Cabin Counselor 
• Volunteered as a camp counselor at Camp Braveheart, a camp for children who 
have had a heart transplant or have a congenital heart disease 
• Responsibilities included not only the traditional camp duties, but serving as a 
role model for the girls in my cabin  
 
Children’s Healthcare of Atlanta, Atlanta, GA | Fall 2009 – Spring 2011 
Hospital College Volunteer 
• Volunteered in the operating room restocking supplies and preparing operating 
rooms 
• Volunteered in the emergency department by interacting with patients and 
families to help pass their time spend in the hospital  
